List of Excipients in Branded Drug LOTRIMIN ULTRA JOCK ITCH

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare LLC	LOTRIMIN ULTRA JOCK ITCH	butenafine hydrochloride	11523-7155	BENZYL ALCOHOL
Bayer HealthCare LLC	LOTRIMIN ULTRA JOCK ITCH	butenafine hydrochloride	11523-7155	CETETH-23
Bayer HealthCare LLC	LOTRIMIN ULTRA JOCK ITCH	butenafine hydrochloride	11523-7155	CETYL ALCOHOL
Bayer HealthCare LLC	LOTRIMIN ULTRA JOCK ITCH	butenafine hydrochloride	11523-7155	DIETHANOLAMINE
Bayer HealthCare LLC	LOTRIMIN ULTRA JOCK ITCH	butenafine hydrochloride	11523-7155	GLYCERIN
Bayer HealthCare LLC	LOTRIMIN ULTRA JOCK ITCH	butenafine hydrochloride	11523-7155	PETROLATUM

Last updated: August 23, 2026

The commercial opportunity for Lotrimin Ultra Jock Itch is primarily an OTC formulation and brand-extension opportunity, not a new-molecule patent opportunity. The product contains butenafine hydrochloride 1% in a conventional cream base and is regulated under the FDA topical antifungal OTC framework. Its principal competitive advantages are once-daily dosing, broad consumer recognition and a differentiated active ingredient. The main barriers to entry are regulatory compliance, product performance, consumer trust and retail distribution rather than an active patent estate.

Lotrimin Ultra Jock Itch Excipient Strategy and Commercial Opportunities

What is Lotrimin Ultra Jock Itch?

Lotrimin Ultra Jock Itch is an OTC topical antifungal cream containing butenafine hydrochloride 1% as the active ingredient. It is indicated for the treatment of tinea cruris, commonly called jock itch. The labeled regimen is once daily for two weeks.[1]

The product is a semisolid oil-in-water cream. Its excipient system supports drug dispersion, skin application, emulsion stability, preservation and acceptable sensory performance.

Attribute	Lotrimin Ultra Jock Itch
Active ingredient	Butenafine hydrochloride 1%
Dosage form	Topical cream
Indication	Jock itch, or tinea cruris
Dosing frequency	Once daily
Regulatory category	OTC topical antifungal
Primary market	United States consumer healthcare
Originator brand	Lotrimin
Likely commercial owner	Bayer Consumer Health
Orange Book status	Generally not applicable to an OTC monograph product
Biosimilar risk	None
Primary substitution risk	OTC generic and store-brand antifungal creams

The product is marketed under the Lotrimin brand, while the FDA Drug Facts framework controls the permitted claims, active ingredient concentration, warnings and directions.[1,2]

What excipients are used in Lotrimin Ultra Jock Itch?

The labeled inactive ingredients are benzyl alcohol, cetyl alcohol, cetyl esters wax, purified water, sodium benzoate, stearyl alcohol and polysorbate 60.[1]

Excipient	Primary formulation role	Commercial or technical relevance
Purified water	Continuous aqueous phase	Controls cream structure, viscosity and skin feel
Cetyl alcohol	Fatty alcohol, emollient and consistency agent	Builds body and improves spreadability
Stearyl alcohol	Fatty alcohol and structuring agent	Supports viscosity and emulsion stability
Cetyl esters wax	Emollient and consistency modifier	Contributes to occlusivity and cream texture
Polysorbate 60	Nonionic surfactant and emulsifier	Stabilizes the oil-in-water emulsion
Benzyl alcohol	Preservative and solvent	Supports microbial control and ingredient solubilization
Sodium benzoate	Preservative	Provides additional antimicrobial protection, subject to pH control
Butenafine hydrochloride	Active antifungal ingredient	Requires uniform distribution and adequate release from the vehicle

The formulation uses a relatively conventional excipient platform. That structure may reduce development risk, but it also creates opportunities for competitors to differentiate through sensory properties, packaging and delivery format.

Why are fatty alcohols important?

Cetyl alcohol and stearyl alcohol provide viscosity and contribute to the cream’s consistency. They are not the same as ethanol-based alcohols. In topical creams, fatty alcohols can improve emollience, reduce runniness and help maintain a stable semisolid matrix.

The ratio of cetyl alcohol, stearyl alcohol and cetyl esters wax can materially change:

• Spreadability
• Residue after application
• Rub-in time
• Whiteness on the skin
• Occlusivity
• Stability during temperature cycling
• Consumer perception of greasiness

A competitor can use the same active ingredient concentration while creating a meaningfully different consumer experience through these variables.

What is the role of polysorbate 60?

Polysorbate 60 is a nonionic surfactant used to support emulsion formation. It can help distribute the oil-phase components through the aqueous phase and maintain physical uniformity.

The key development risks are phase separation, viscosity drift, active sedimentation or crystallization, and changes in droplet size during storage. These risks require stability testing under long-term, accelerated and freeze-thaw conditions.

Why does preservative selection matter?

Benzyl alcohol and sodium benzoate provide a preservative system, but preservative performance depends on pH, water activity, packaging, microbial challenge results and manufacturing controls.

A reformulated product could pursue:

• A lower-sensitization preservative system
• A preservative-free presentation in a single-use format
• An airless package that reduces repeated microbial exposure
• A lower-water or anhydrous system
• A package with improved protection against contamination in bathroom environments

Any change must preserve antimicrobial protection and comply with OTC monograph requirements, labeling rules and applicable quality standards.

What formulation patents protect Lotrimin Ultra Jock Itch?

No active, product-specific patent barrier should be assumed for the current Lotrimin Ultra Jock Itch cream. The product is an OTC monograph-style topical antifungal, and the FDA public labeling framework does not identify a current formulation patent that would prevent competing butenafine products from entering the U.S. market.[1,2]

The relevant intellectual-property categories are:

IP category	Relevance to Lotrimin Ultra
Butenafine compound patents	Historical originator protection; unlikely to block current OTC entry
Cream formulation patents	Potentially relevant only if a specific formulation or process remains enforceable
Method-of-use patents	Limited value where the treatment indication is covered by OTC labeling
Trademark rights	Lotrimin and product branding remain commercially important
Packaging patents	May protect a dispenser or application system, but not the core cream
Manufacturing know-how	Can affect scale-up, stability and product quality without being publicly visible

A competitor should not rely only on a patent search. Freedom-to-operate analysis should also cover trademarks, trade dress, regulatory exclusivity, supplier agreements, manufacturing know-how and any jurisdiction-specific rights.

Are there Orange Book listings for Lotrimin Ultra?

Lotrimin Ultra is generally not an Orange Book-listed prescription product. The Orange Book primarily covers approved prescription drugs, certain approved nonprescription drugs and their listed patents or exclusivities. An OTC product marketed under the topical antifungal monograph does not normally create the same Orange Book patent-certification pathway as a conventional approved prescription NDA.[3]

This distinction affects entry strategy. A competitor may be able to develop a compliant OTC monograph product without filing an ANDA or making a Paragraph IV certification against an Orange Book patent.

When does Lotrimin Ultra lose exclusivity?

Lotrimin Ultra does not have a conventional prescription-drug exclusivity date controlling market entry. Its commercial exclusivity is based on brand recognition, retail placement, consumer advertising, formulation execution and trademark protection.

The active ingredient and topical antifungal category are subject to the FDA OTC monograph framework. Butenafine hydrochloride 1% is recognized as an OTC topical antifungal active ingredient under the applicable FDA requirements.[2]

Exclusivity mechanism	Status
New chemical entity exclusivity	Not applicable to the current OTC product
Prescription NDA exclusivity	Not the primary framework
Orange Book patent exclusivity	Generally not applicable
Paragraph IV pathway	Generally not applicable to a monograph product
OTC monograph compliance	Primary regulatory entry route
Trademark exclusivity	Important for Lotrimin branding
Retail and advertising advantage	Major practical barrier

The earliest practical generic-entry scenario is therefore driven by manufacturing readiness, monograph compliance, retailer acceptance and launch economics rather than by a single patent expiration date.

Are Paragraph IV challenges possible against Lotrimin Ultra?

A conventional Paragraph IV challenge is generally not the expected route for a product marketed under an OTC monograph. Paragraph IV certifications are associated with abbreviated applications referencing an approved drug listed in the Orange Book.[3]

A competitor pursuing a butenafine 1% jock itch product may instead:

1. Develop a formulation compliant with the FDA topical antifungal monograph.
2. Conduct product quality, stability and microbial testing.
3. Prepare Drug Facts labeling.
4. Confirm active ingredient identity, strength and dosage form.
5. Manufacture under applicable current good manufacturing practice requirements.
6. Launch under a private label, store brand or independent OTC brand.

A separate FDA application could become relevant if the product makes claims, uses an active ingredient, or adopts a delivery system outside the monograph conditions.

What excipient strategies could compete with Lotrimin Ultra?

Low-residue cream

The most direct opportunity is a cream that reduces greasiness and visible residue. This could be achieved by adjusting the oil phase, reducing heavy wax content, optimizing droplet size and using a lighter emollient system.

The commercial claim would likely focus on cosmetic properties rather than a superior antifungal claim unless supported by appropriate evidence.

Fast-absorbing gel-cream

A gel-cream could target consumers who reject traditional creams because of tackiness or prolonged wetness. The formulation would need to maintain butenafine solubility or uniform dispersion while delivering adequate skin deposition.

Potential risks include:

• Active crystallization
• Loss of viscosity
• Irritation from high solvent levels
• Reduced residence time
• Poor performance on moist or macerated skin

Spray or aerosol

A spray could improve convenience and reduce direct finger contact. It may appeal to consumers treating large or difficult-to-reach areas.

A spray presentation introduces technical and regulatory complexity involving:

• Propellant or pump compatibility
• Dose uniformity
• Flammability, if volatile solvents are used
• Inhalation and ocular exposure controls
• Container-closure integrity
• Spray pattern and coverage
• Labeling for use near sensitive areas

A non-aerosol pump spray is generally a lower-complexity starting point than a pressurized aerosol.

Foam

Foams can provide quick application and low perceived residue. They also offer a differentiated retail presentation. The main risks are active uniformity, foam collapse, packaging compatibility and reproducible dosing.

A butenafine foam would require comparative development work to demonstrate that the new vehicle provides acceptable delivery and stability relative to the established cream.

Preservative-reduced or preservative-free format

Consumers with sensitive skin may prefer a low-preservative product. A single-use sachet, unit-dose applicator or airless pump could reduce microbial exposure.

This strategy creates packaging cost and supply-chain complexity. It may be commercially attractive for premium positioning but less competitive in the mass OTC channel.

Fragrance-free and sensitive-skin positioning

The labeled Lotrimin Ultra ingredient list does not identify a fragrance component.[1] A competing product could still emphasize dermatological testing, reduced irritancy, nonstaining behavior or compatibility with sensitive skin, provided claims are properly substantiated and do not imply unsupported superiority.

How strong is the patent estate for Lotrimin Ultra?

The patent estate appears weak as a current barrier to ordinary OTC competition. The stronger assets are likely non-patent commercial assets:

• Lotrimin trademark recognition
• Retail shelf position
• Consumer search demand
• Retailer relationships
• National advertising
• Manufacturing scale
• Established product reviews
• Familiar once-daily dosing

A reformulated delivery system could create new patentable subject matter if it demonstrates a novel composition, packaging system, manufacturing process or performance characteristic. Patentability would depend on novelty, non-obviousness and adequate disclosure under applicable law.

Potentially protectable areas include:

• Specific butenafine solubilization systems
• Low-residue cream compositions
• Stable non-aqueous vehicles
• Unit-dose application systems
• Spray or foam delivery platforms
• Manufacturing processes that control active particle size
• Packaging that improves microbial robustness or dose consistency

A patent covering only routine substitution of one emollient or surfactant for another would face a higher obviousness risk.

What generic launch risks exist?

The principal launch risks are commercial and regulatory.

Risk	Impact
Weak consumer differentiation	High
Retailer preference for established Lotrimin	High
Low-cost store-brand competition	High
Poor cream sensory profile	Medium to high
Stability failure	High
Preservative challenge failure	High
Active crystallization	High
Inadequate manufacturing scale	Medium
Trademark or trade-dress conflict	Medium
Limited advertising budget	High

A low-cost cream can enter with limited clinical development if it remains within the OTC monograph framework, but commercial success still depends on product quality and retailer access.

How does Lotrimin Ultra compare with competing antifungals?

Product category	Active ingredient	Typical dosing positioning	Main competitive advantage
Lotrimin Ultra	Butenafine hydrochloride 1%	Once daily for two weeks	Once-daily branded cream
Lamisil AT	Terbinafine hydrochloride 1%	Product-specific regimen	Strong consumer recognition and allylamine positioning
Lotrimin AF	Clotrimazole 1% or miconazole 2%, depending on product	Often more frequent use	Broad availability and lower-cost alternatives
Store-brand products	Clotrimazole, miconazole, terbinafine or butenafine	Varies by active ingredient	Price and retailer control

The strongest opportunity is not necessarily to copy the active ingredient. A competitor could win through a better vehicle, a lower price, a more convenient delivery system or stronger retailer economics.

What licensing opportunities exist?

Licensing opportunities are more likely to involve formulation technology, packaging or distribution than the butenafine molecule.

Potential deal structures include:

• Licensing a low-residue topical platform to an OTC brand owner
• Supplying a private-label butenafine cream to a national retailer
• Acquiring a regional antifungal brand with established shelf space
• Licensing a pump, foam or spray package
• Partnering with a contract manufacturer that has validated topical capabilities
• Commercializing a sensitive-skin or dermatology-focused extension

The most valuable partner would typically provide one of three assets: regulatory-ready formulation, scalable manufacturing or established retail distribution.

What is the FDA regulatory status of Lotrimin Ultra?

Lotrimin Ultra is an OTC topical antifungal product using butenafine hydrochloride 1%. The FDA topical antifungal monograph establishes conditions for active ingredients, concentrations, indications, labeling and directions.[1,2]

The product must comply with:

• Active ingredient strength requirements
• Drug Facts labeling
• Manufacturing quality standards
• Stability and package compatibility expectations
• Microbial quality requirements
• Advertising and labeling restrictions
• OTC monograph conditions for topical antifungal products

Claims involving faster cure, superior efficacy, recurrence prevention or treatment of infections outside the labeled indication require careful regulatory review and supporting evidence.

What revenue exposure does Lotrimin Ultra create?

Public product-level revenue for Lotrimin Ultra Jock Itch is not generally reported separately from the broader Lotrimin and Bayer Consumer Health portfolio. The commercial exposure is therefore best assessed through category economics rather than a product-specific revenue figure.

The principal revenue sensitivities are:

• Seasonal demand during warm-weather months
• Retail promotion and shelf placement
• Price competition from store brands
• Consumer migration to terbinafine products
• Growth of e-commerce search and fulfillment
• Premium pricing for improved sensory properties
• Cross-selling across jock itch, athlete’s foot and ringworm indications

A new entrant could pursue a value strategy with a low-cost cream or a premium strategy with a cleaner-feeling, faster-absorbing product. The premium strategy offers greater margin potential but requires stronger consumer evidence and packaging execution.

Key Takeaways

• Lotrimin Ultra Jock Itch contains butenafine hydrochloride 1% in a conventional cream vehicle.
• The labeled excipients are benzyl alcohol, cetyl alcohol, cetyl esters wax, purified water, sodium benzoate, stearyl alcohol and polysorbate 60.
• The product’s practical exclusivity is based on brand, retail distribution and consumer recognition rather than an apparent active patent barrier.
• Orange Book listing and Paragraph IV litigation are generally not the central entry mechanisms for this OTC monograph product.
• The strongest formulation opportunities are low-residue creams, gel-creams, sprays, foams, unit-dose formats and sensitive-skin presentations.
• Commercial entrants face greater risk from retailer access, product feel, pricing and manufacturing execution than from molecule-level intellectual property.
• New patent opportunities may exist around delivery systems, packaging, solubilization and manufacturing controls.

FAQs

Can a private-label company sell a butenafine 1% jock itch cream?

Yes, a private-label company can pursue an OTC product that complies with the applicable FDA topical antifungal monograph, manufacturing requirements and Drug Facts labeling rules.

Is butenafine hydrochloride more commercially differentiated than clotrimazole?

Yes. Butenafine can support once-daily positioning, while many clotrimazole products require more frequent application. Commercial differentiation still depends on label-compliant claims, price and consumer awareness.

Could an airless pump create a defensible OTC product?

An airless pump could improve dispensing, contamination control and premium positioning. Patent protection would depend on the specific package design and technical claims, not merely the use of an airless container.

What is the lowest-risk formulation alternative to the existing Lotrimin Ultra cream?

A closely comparable oil-in-water cream with the same active ingredient and concentration presents the lowest technical risk. Its commercial differentiation would likely come from excipient ratios, skin feel, packaging and price.

Does Lotrimin Ultra create biosimilar competition?

No. Lotrimin Ultra contains a synthetic small-molecule antifungal, not a biologic. Competition would come from generic, private-label and reformulated OTC antifungal products.

References

1. DailyMed. (n.d.). Lotrimin Ultra: Butenafine hydrochloride cream, 1% drug labeling. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2022). OTC monograph M005: Topical antifungal drug products for over-the-counter human use. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.